Pay in 4 interest-free payments of $5.44 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Cigna drops coverage of GLP-1 obesity drugs for its own employees NEW YORK Health insurer Cigna will stop covering GLP-1 weight-loss drugs, including Novo Nordisk's Wegovy and Eli Lilly's Zepbound, in its employee health plan effective July 1, according to materials viewed by Reuters.
As research yields new insights and potential therapies, the market is expected to benefit from a pipeline of novel products that could reshape treatment paradigms
Injection Timing: Semaglutide is injected once weekly on the same day
In patients with type 2 diabetes, treatment with semaglutide 1 mg resulted in reductions in glucose in terms of absolute change from baseline and relative reduction compared to placebo of 29 mg/dL (22%) for fasting glucose, 74 mg/dL (36%) for 2-hour postprandial glucose, and 30 mg/dL (22%) for mean 24-hour glucose concentration (see Figure 1)
As an increasing number of clinical trials explore newly engineered oncolytic virotherapies, these advancements are poised to yield significant breakthroughs in related research and promote the widespread adoption of oncolytic virotherapy for cancer treatment
It is a biased dual agonist with preference for the GIP receptor [7, 8, 9]
